2026.06.24
On June 24, 2026, Shaanxi Micot Pharmaceutical Technology Co. (Micot, stock code: 2335.HK) was listed on the main board of the Hong Kong Stock Exchange and became the first innovative polypeptide drug stock in Hong Kong and the first company from Northwest China to be listed under the 18A rule. Micot issued 58,054,400 H shares globally at an issue price of HKD 18.2 per share, raising a total of HKD 1.0566 billion. JunHe served as the company's domestic legal counsel and provided comprehensive legal services for Micot's Hong Kong listing.
Founded in 2007, Micot is an innovative pharmaceutical technology company focused on new drug research and development. It specializes in discovering, developing and commercializing dual/multi-specific peptide drugs for the treatment of metabolic and cardiovascular diseases. The company has independently developed a product pipeline consisting of one core product and six other candidate products. The core product, MT1013, is a self-developed dual-target receptor agonist peptide in Phase III and is designed to target CaSR and OGP receptors simultaneously. This is primarily for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD-SHPT), with potential expansion to other indications such as mineral and bone metabolism disorders in chronic kidney disease with osteoporosis (CKD-MBD) and non-dialysis CKD-SHPT.
JunHe was the company's domestic legal advisor for this project. We conducted comprehensive domestic legal due diligence, issued Chinese legal opinions, drafted, reviewed, and revised the application and issuance documents related to the listing and prepared a full set of legal documents for the China Securities Regulatory Commission (CSRC) overseas listing filing. JunHe also assisted the company in communicating with the CSRC and responded to feedback from the CSRC, the Hong Kong Securities and Futures Commission (SFC), and the Hong Kong Stock Exchange regarding the various domestic legal issues related to the listing application. JunHe's rigorous, meticulous and comprehensive legal services have been highly recognized and appreciated by Micot and the other intermediary institutions.
The lead partner for this project was TAO, Xudong . ZHOU, Fang was the internal review partner.
